Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137111 · ClinicalTrials.gov registry record · Phase 3
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
A Phase 3 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 501
- Enrollment target
NCT00137111 is a Phase 3 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 501 participants.
The verdict
NCT00137111, a Phase 3 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 501 participants
- Enrollment target
Study Summary
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
Interventions
- DRUG Prednisone, Dexamethasone, Vincristine, Daunorubicin
- DRUG Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
- DRUG Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
- DRUG Mercaptopurine, Imatinib
- PROCEDURE chemotherapy, intrathecal chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2000-07-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137111
The ClinicalTrials.gov registry entry for NCT00137111 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Prednisone, Dexamethasone, Vincristine, Daunorubicin is the first listed.
NCT00137111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00137111 about?
NCT00137111 is a clinical study titled "Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia". The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
What is the current status of trial NCT00137111?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 501 participants. The study started on 2000-07-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00137111?
The interventions under investigation include: Prednisone, Dexamethasone, Vincristine, Daunorubicin (DRUG), Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase (DRUG), Methotrexate, Cyclophosphamide, Cytarabine, Etoposide (DRUG), Mercaptopurine, Imatinib (DRUG), chemotherapy, intrathecal chemotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00137111?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.